Second Generation Cell and Gene-based Therapies

  • ID: 4539987
  • Book
  • 500 Pages
  • Elsevier Science and Technology
1 of 4

Second Generation Cell and Gene-Based Therapies: Biological Advances, Clinical Outcomes, and Strategies for Capitalization serves as the only book on the market to bridge basic science, clinical therapy, technology development and business in the field of cellular therapy/cytotherapy. After more than two decades of painstaking fundamental research, the concept of therapeutic cells (stem cells, genes, etc.), beyond the concept of vaccines is reaching clinical trial, with mounting confidence in the safety and efficacy of these products. Nonetheless, numerous incremental technical advances remain to be achieved. Thus, this volume highlights the possible R&D paths that will ultimately facilitate clinical delivery of cutting-edge, curative products.

Chapters cover hematopoietic stem cells, mesenchymal stem cells, tissue engineering, CAR-T cells, and cells of the immune system, as well as enabling technologies, such as gene and genome editing. Additionally, deep dives in product fundamentals, the history of the science, the pathobiology of diseases, the scientific and technological bases, and financing and technology adoption constraints are taken in order to unravel what will shape the cytotherapy industry in 2025 and beyond.

  • Helps readers learn about the most current trends in cell-based therapy, their overall effectiveness from a clinical prospective, and how the industry is moving therapies forward for capitalization
  • Perspectives section at the end of each chapter summarizes key learnings, hypotheses, and objectives highlighted
  • Edited and authored by scientists representing both basic and clinical research and industry, presenting a complete story of the current state and future promise of cellular therapies
Note: Product cover images may vary from those shown
2 of 4

PART I: SCIENCE 1. Riding the technology S-curves in cytotherapies 2. Gene therapy 3. Therapeutic potential of cells of the immune system 4. T-cell engineering 5. Engineered hematopoietic stem cells 6. Second generation MSCs 7. First generation induced Pluripotent Stem Cells 8. Editing technologies for the mammalian genomes 9. The Next Wave:  Tissue Replacement and Organ Replacement

PART II: TRANSLATION 10. Gene Therapy clinical trials 11. CAR T-cells clinical trials 12. Cytotherapy clinical trials in genetic disorders of the blood 13. Late stage Clinical trials data from minimally manipulated MSCs and translational advances with genetically engineered MSCs

PART III: THE NEXT FRONTIER 14. Second generation genome editing technologies in drug discovery 15. Harnessing the therapeutic potential of dendritic cells 16: Second generation CAR T-cells 17. Capitalising on the potential of neural stem cells in oncology and CNS 18. Combinatory cytotherapy

PART IV: PERSPECTIVES 19.  Cytotherapy manufacturing: service-based business model vs. off-the-shelf blockbuster business model 20: Second generation cytotherapy business models: the case of CAR-T cells business sustainability 21. Financing the new wave of transformational oncology treatments 22. Strategic alliances in cytotherapies and gene therapies. Funding the new wave of cell therapeutics 23. Solid tumor immune-oncology

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Vertes, Alain
University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flanders-Artois

. Sloan Fellow from London Business School and a microbiologist by training (University of Illinois at Urbana-Champaign, Institut Pasteur Paris, and University of Lille Flandres-Artois).

. Consulting, Partnering & Fund Raising, Founder, Managing Director, NxR Biotechnologies, Switzerland.

. Dr. Vertès is a strategy and business development consultant for cell therapeutic biotech companies, and works to enable seed funding in the field. Focusing on technology deployment and innovation commercialization, he has contributed to both industrial and pharmaceutical biotechnology, in different functions including research, manufacturing, contract research, and strategic alliances in pharmaceuticals (Lilly, Pfizer, Roche).

. Championed radical innovation for bringing to patients disease-modifying, paradigm-changing therapeutics such as siRNA, and led in a scientific and business manner Roche's global cell therapeutics strategy and implementation team resulting in Roche's entry in 2010 in the field of regenerative medicine.

. Member, Industry Committee-Europe, Tissue Engineering and Regenerative Medicine International Society

. Co-Editor, Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies (Wiley, 2015).
Dowden, Nathan J.
Smith, Devyn
. Head of Operations & Strategy, Medicinal Sciences Division of R&D, Pfizer Inc.

. Responsible for all cell & gene therapy products, as well as previously developing Pfizer's Regenerative Medicine program.

. PhD in Genetics from Harvard Medical School.

. Adjunct faculty member at Northeastern University.
Qureshi, Nasib
US Department of Agriculture, National Center for Agricultural Utilization Research, Bioenergy Research Unit, Peoria, IL US
US Department of Agriculture, National Center for Agricultural Utilization Research, Peoria, IL US
. Senior Researcher/Senior Scientist, United States Department of Agriculture, National Center for Agricultural Utilization Research, Bioenergy Research Unit.
. Affiliate Faculty, Institute for Genomic Biology, Univ. of Illinois.
. Adjunct Professor (Biochemical Engineering), University of Illinois.
. EIC, World Journal of Microbiology & Biotechnology (Springer).
. Co-Editor, Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies (Wiley, 2015).

Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll